ArticleFrontiers in pharmacology2021

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report.

Yadong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.